Resolution of Thyroid Acropachy in a Patient Treated With Teprotumumab: A Case Report and Review of Mechanisms
Graves’ disease is an autoimmune thyroidopathy associated with hyperthyroidism and nonendocrine manifestations such as thyroid eye disease (TED), pretibial myxedema, and thyroid acropachy. Thyroid acropachy is an uncommon but debilitating condition, typically characterized by digital clubbing, soft...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-01-01
|
| Series: | Case Reports in Endocrinology |
| Online Access: | http://dx.doi.org/10.1155/crie/5544869 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850071793557045248 |
|---|---|
| author | Soumya Chatterjee |
| author_facet | Soumya Chatterjee |
| author_sort | Soumya Chatterjee |
| collection | DOAJ |
| description | Graves’ disease is an autoimmune thyroidopathy associated with hyperthyroidism and nonendocrine manifestations such as thyroid eye disease (TED), pretibial myxedema, and thyroid acropachy. Thyroid acropachy is an uncommon but debilitating condition, typically characterized by digital clubbing, soft tissue swelling, and periosteal new bone formation in the hands and feet. This condition often accompanies TED and dermopathy, but effective treatments remain elusive. The first documented case of thyroid acropachy successfully treated with teprotumumab, a monoclonal antibody targeting the insulin-like growth factor-1 receptor (IGF-1R), is reported here. A 49-year-old female with a history of Graves’ disease developed severe musculoskeletal symptoms, including clubbing and periosteal new bone formation. Despite initial therapies with rituximab and intravenous immunoglobulin showing limited benefit, treatment with teprotumumab, primarily prescribed for TED, led to significant clinical and radiological improvement. After completing eight cycles of teprotumumab, the patient’s musculoskeletal pain resolved, clubbing regressed, and radiologic findings of periosteal bone formation diminished. This case highlights the potential of teprotumumab as a novel therapeutic option for thyroid acropachy and suggests that IGF-1R plays a crucial role in its pathogenesis. While this report presents promising results, further studies are needed to confirm the efficacy of teprotumumab in treating thyroid acropachy and better understand its long-term effects on this rare condition. |
| format | Article |
| id | doaj-art-eccda5da842442509bfc8258dcfffe1a |
| institution | DOAJ |
| issn | 2090-651X |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Endocrinology |
| spelling | doaj-art-eccda5da842442509bfc8258dcfffe1a2025-08-20T02:47:13ZengWileyCase Reports in Endocrinology2090-651X2025-01-01202510.1155/crie/5544869Resolution of Thyroid Acropachy in a Patient Treated With Teprotumumab: A Case Report and Review of MechanismsSoumya Chatterjee0Cleveland Clinic Lerner College of Medicine of Case Western Reserve UniversityGraves’ disease is an autoimmune thyroidopathy associated with hyperthyroidism and nonendocrine manifestations such as thyroid eye disease (TED), pretibial myxedema, and thyroid acropachy. Thyroid acropachy is an uncommon but debilitating condition, typically characterized by digital clubbing, soft tissue swelling, and periosteal new bone formation in the hands and feet. This condition often accompanies TED and dermopathy, but effective treatments remain elusive. The first documented case of thyroid acropachy successfully treated with teprotumumab, a monoclonal antibody targeting the insulin-like growth factor-1 receptor (IGF-1R), is reported here. A 49-year-old female with a history of Graves’ disease developed severe musculoskeletal symptoms, including clubbing and periosteal new bone formation. Despite initial therapies with rituximab and intravenous immunoglobulin showing limited benefit, treatment with teprotumumab, primarily prescribed for TED, led to significant clinical and radiological improvement. After completing eight cycles of teprotumumab, the patient’s musculoskeletal pain resolved, clubbing regressed, and radiologic findings of periosteal bone formation diminished. This case highlights the potential of teprotumumab as a novel therapeutic option for thyroid acropachy and suggests that IGF-1R plays a crucial role in its pathogenesis. While this report presents promising results, further studies are needed to confirm the efficacy of teprotumumab in treating thyroid acropachy and better understand its long-term effects on this rare condition.http://dx.doi.org/10.1155/crie/5544869 |
| spellingShingle | Soumya Chatterjee Resolution of Thyroid Acropachy in a Patient Treated With Teprotumumab: A Case Report and Review of Mechanisms Case Reports in Endocrinology |
| title | Resolution of Thyroid Acropachy in a Patient Treated With Teprotumumab: A Case Report and Review of Mechanisms |
| title_full | Resolution of Thyroid Acropachy in a Patient Treated With Teprotumumab: A Case Report and Review of Mechanisms |
| title_fullStr | Resolution of Thyroid Acropachy in a Patient Treated With Teprotumumab: A Case Report and Review of Mechanisms |
| title_full_unstemmed | Resolution of Thyroid Acropachy in a Patient Treated With Teprotumumab: A Case Report and Review of Mechanisms |
| title_short | Resolution of Thyroid Acropachy in a Patient Treated With Teprotumumab: A Case Report and Review of Mechanisms |
| title_sort | resolution of thyroid acropachy in a patient treated with teprotumumab a case report and review of mechanisms |
| url | http://dx.doi.org/10.1155/crie/5544869 |
| work_keys_str_mv | AT soumyachatterjee resolutionofthyroidacropachyinapatienttreatedwithteprotumumabacasereportandreviewofmechanisms |